Trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
[]
 tdxd as effective in non-asian population compared to asian dg02 trial results @ #esmo22 orr 41.8% mos &gt; 12.1 months should we have european license? great discussion by 
Medical Oncologist.  Cancer Researcher. ???? in ???? ?? ??????.  Always falling over and getting back up again.